Invitae has launched 24 new and expanded 19 genetic test panels, allowing clinicians to gain information on 183 new genes with clinical and diagnostic significance. This launch represents a significant expansion of the company’s pediatric, neurological, and rare disease offerings, which include tests for genes associated with epilepsy, developmental disorders, overgrowth syndromes, and skeletal disorders, as well as tests in dermatology, immunology, and ophthalmology.

The panels provide clinicians, patients, and payers greater flexibility to access high-quality, affordable genetic information across a larger number of pediatric and neurological disorders, as well as rare diseases, all at the same price. Results are provided quickly, within 14 days on average.

Invitae’s expanded offering includes:

• Comprehensive testing for epilepsy and epilepsy-related disorders
• Expansion of panels testing for developmental disorders, overgrowth syndromes, skeletal disorders, and RASopathies/Noonan spectrum disorders
• Incorporation of the latest genetic findings for ciliopathies into an expanded panel
• Consolidation of clinical areas enabling customers to order a broader set of tests that are relevant for the patient at a single price and with a single specimen

The new and expanded panels are available immediately. Detailed information can be found here.